53813-83-5CN1CCN(C(=O)OC2C3=C(SCCS3)C(=O)N2c2ccc3ccc(Cl)nc3n2)CC1RMXOUBDDDQUBKD-UHFFFAOYSA-Nrecognizes receptors labeled by benzodiazepines
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
DescriptionSuriclone is one of the most potent of all agents known to act at the benzodiazepine receptor. Its anxiolytic effects have been clearly demonstrated in rodents (Doble et al. 1992). It has also been demonstrated to be efficacious in the treatment of generalized anxiety disorder in humans (Ansseau et al. 1991). Animal work has shown it to have fewer side effects and less potential for interacting with alcohol than do benzodiazepines. These would represent significant advantages if they were also seen in humans. Repeated doses have failed to show tolerance and do not produce the change in “set point” of the GABAA receptor seen with the benzodiazepines. The reason for this is unclear but may be linked to a difference in the interaction of the cyclopyrrolones with the receptor compared with that of the benzodiazepines.
UsesSuriclone (RP31264) is a GABA receptor agonist. Suriclone is an anxiolytic agent with a high affinity for the benzodiazepine receptors. Suriclone has oral activity[1].
No reaction records under the current filter.
Loading…
53813-83-5DTXSID20866362CHEMBL2105561